1. 1464PKEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. (23rd October 2018) Authors: Rodriguez Abreu, D; Garassino, M C; Esteban, E; Speranza, G; Felip, E; Domine, M; Hochmair, M J; Powell, S F; Cheng, S Y-S; Bischoff, H; Peled, N; Hui, R; Reck, M; Garon, E B; Boyer, M; Grossi, F; Jennens, R; Yang, J; Pietanza, M C; Gadgeel, S M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. (2nd February 2018) Authors: Vokes, E E; Ready, N; Felip, E; Horn, L; Burgio, M A; Antonia, S J; Arén Frontera, O; Gettinger, S; Holgado, E; Spigel, D; Waterhouse, D; Domine, M; Garassino, M; Chow, L Q M; Blumenschein, G; Barlesi, F; Coudert, B; Gainor, J; Arrieta, O; Brahmer, J Journal: Annals of oncology Issue: Volume 29:Number 4(2018) Page Start: 959 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗